FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094322208> ?p ?o ?g. }

• W2094322208 endingPage "811" @default.
• W2094322208 startingPage "805" @default.
• W2094322208 abstract "We treated 60 relapsed/refractory mixed-phenotype acute leukemia patients (MPAL-1) with increasing the aclarubicin dose in CAG regimen (HD-CAG, cytarabine (10 mg/m(2)/12 h, days 1-14), aclarubicin (5-7 mg/m(2)/day, days 1-14), granulocyte colony-stimulating factor (200 μg/m(2)/day, days 1-14). This was compared to 64 relapsed/refractory MPAL patients (MPAL-2) treated with DOAP regimen (daunorubicin, vincristine/vindesine, cytarabine and prednisone), 113 relapsed/refractory acute myeloid leukemia (AML) patients and 78 acute lymphocytic leukemia (ALL) patients treated with HD-CAG regimen. After one course, complete remission (CR) and overall response [OR, CR+partial remission (PR)] rates for MPAL-1 exceeded MPAL-2 (CR, 61.02% vs. 28.13%, P=0.000; OR, 72.88% vs. 34.38%, P=0.000), but these data were similar to AML and ALL (P>0.05). In MPAL-1 group, CR and OR rates of T-lymphoid+myeloid immunophenotype were higher than B-lymphoid+myeloid immunophenotype (CR, 81.82% vs. 44.12%, P=0.005; OR, 90.91% vs. 58.82%, P=0.009). The overall survival at 3 years in MPAL-1, MPAL-2, AML and ALL groups were 14.2%±6.8%, 14.1%±6.4%, 17.3%±5.0% and 15.0%±5.3% (P>0.05). Side effects were similar between HD-CAG and DOAP (P>0.05). HD-CAG regimen is efficacious for relapsed/refractory MPAL, especially for T+My patients." @default.
• W2094322208 created "2016-06-24" @default.
• W2094322208 creator A5002331703 @default.
• W2094322208 creator A5002430497 @default.
• W2094322208 creator A5034456024 @default.
• W2094322208 creator A5044756293 @default.
• W2094322208 creator A5063447635 @default.
• W2094322208 creator A5076039953 @default.
• W2094322208 creator A5077384746 @default.
• W2094322208 date "2015-08-01" @default.
• W2094322208 modified "2023-09-25" @default.
• W2094322208 title "Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia" @default.
• W2094322208 cites W1555883714 @default.
• W2094322208 cites W1572192022 @default.
• W2094322208 cites W1976278222 @default.
• W2094322208 cites W1995297095 @default.
• W2094322208 cites W2005253891 @default.
• W2094322208 cites W2025046806 @default.
• W2094322208 cites W2051643118 @default.
• W2094322208 cites W2053946997 @default.
• W2094322208 cites W2055012214 @default.
• W2094322208 cites W2058794167 @default.
• W2094322208 cites W2068981404 @default.
• W2094322208 cites W2071984928 @default.
• W2094322208 cites W2086863372 @default.
• W2094322208 cites W2119932793 @default.
• W2094322208 cites W2147843594 @default.
• W2094322208 doi "https://doi.org/10.1016/j.leukres.2015.04.006" @default.
• W2094322208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26021434" @default.
• W2094322208 hasPublicationYear "2015" @default.
• W2094322208 type Work @default.
• W2094322208 sameAs 2094322208 @default.
• W2094322208 citedByCount "8" @default.
• W2094322208 countsByYear W20943222082015 @default.
• W2094322208 countsByYear W20943222082016 @default.
• W2094322208 countsByYear W20943222082018 @default.
• W2094322208 countsByYear W20943222082020 @default.
• W2094322208 countsByYear W20943222082022 @default.
• W2094322208 countsByYear W20943222082023 @default.
• W2094322208 crossrefType "journal-article" @default.
• W2094322208 hasAuthorship W2094322208A5002331703 @default.
• W2094322208 hasAuthorship W2094322208A5002430497 @default.
• W2094322208 hasAuthorship W2094322208A5034456024 @default.
• W2094322208 hasAuthorship W2094322208A5044756293 @default.
• W2094322208 hasAuthorship W2094322208A5063447635 @default.
• W2094322208 hasAuthorship W2094322208A5076039953 @default.
• W2094322208 hasAuthorship W2094322208A5077384746 @default.
• W2094322208 hasConcept C126322002 @default.
• W2094322208 hasConcept C141071460 @default.
• W2094322208 hasConcept C142424586 @default.
• W2094322208 hasConcept C2776694085 @default.
• W2094322208 hasConcept C2776755627 @default.
• W2094322208 hasConcept C2777767877 @default.
• W2094322208 hasConcept C2778041864 @default.
• W2094322208 hasConcept C2778729363 @default.
• W2094322208 hasConcept C2779429289 @default.
• W2094322208 hasConcept C2780847677 @default.
• W2094322208 hasConcept C2781413609 @default.
• W2094322208 hasConcept C71924100 @default.
• W2094322208 hasConcept C86803240 @default.
• W2094322208 hasConcept C87355193 @default.
• W2094322208 hasConcept C90924648 @default.
• W2094322208 hasConceptScore W2094322208C126322002 @default.
• W2094322208 hasConceptScore W2094322208C141071460 @default.
• W2094322208 hasConceptScore W2094322208C142424586 @default.
• W2094322208 hasConceptScore W2094322208C2776694085 @default.
• W2094322208 hasConceptScore W2094322208C2776755627 @default.
• W2094322208 hasConceptScore W2094322208C2777767877 @default.
• W2094322208 hasConceptScore W2094322208C2778041864 @default.
• W2094322208 hasConceptScore W2094322208C2778729363 @default.
• W2094322208 hasConceptScore W2094322208C2779429289 @default.
• W2094322208 hasConceptScore W2094322208C2780847677 @default.
• W2094322208 hasConceptScore W2094322208C2781413609 @default.
• W2094322208 hasConceptScore W2094322208C71924100 @default.
• W2094322208 hasConceptScore W2094322208C86803240 @default.
• W2094322208 hasConceptScore W2094322208C87355193 @default.
• W2094322208 hasConceptScore W2094322208C90924648 @default.
• W2094322208 hasFunder F4320327518 @default.
• W2094322208 hasFunder F4320328374 @default.
• W2094322208 hasIssue "8" @default.
• W2094322208 hasLocation W20943222081 @default.
• W2094322208 hasLocation W20943222082 @default.
• W2094322208 hasOpenAccess W2094322208 @default.
• W2094322208 hasPrimaryLocation W20943222081 @default.
• W2094322208 hasRelatedWork W1148551369 @default.
• W2094322208 hasRelatedWork W1932823177 @default.
• W2094322208 hasRelatedWork W2041988411 @default.
• W2094322208 hasRelatedWork W2074820285 @default.
• W2094322208 hasRelatedWork W2101451567 @default.
• W2094322208 hasRelatedWork W2294565310 @default.
• W2094322208 hasRelatedWork W2365810013 @default.
• W2094322208 hasRelatedWork W2585672744 @default.
• W2094322208 hasRelatedWork W2912992975 @default.
• W2094322208 hasRelatedWork W2951177104 @default.
• W2094322208 hasVolume "39" @default.
• W2094322208 isParatext "false" @default.
• W2094322208 isRetracted "false" @default.
• W2094322208 magId "2094322208" @default.

• next